e Tristetraprolin (TTP) acts by binding to AU-rich elements in certain mRNAs, such as tumor necrosis factor (TNF) mRNA, and increasing their decay rates. TTP knockout mice exhibit a profound inflammatory syndrome that is largely due to increased TNF levels. Although TTP's effects on gene expression have been well studied in cultured cells, little is known about its functions in intact tissues. We performed deep RNA sequencing on spleens from TTP knockout mice that were also deficient in both TNF receptors ("triple knockout" mice) to remove the secondary effects of excess TNF activity. To help identify posttranscriptionally regulated transcripts, we also compared changes in mature mRNA levels to levels of transiently expressed pre-mRNA. In the triple knockout spleens, levels of 3,014 transcripts were significantly affected by 1.5-fold or more, but only a small fraction exhibited differential mRNA/pre-mRNA changes suggestive of increased mRNA stability. Transferrin receptor mRNA, which contains two highly conserved potential TTP binding sites, was significantly upregulated relative to its pre-mRNA. This was reflected in increased transferrin receptor expression and increased splenic iron/hemosiderin deposition. Our results suggest that TTP deficiency has profound effects on the splenic transcriptome, even in the absence of secondary increases in TNF activity.
Members of the tristetraprolin (TTP) family of CCCH tandem zinc finger proteins can bind to AU-rich elements (AREs) in the 3= untranslated regions (3=UTR) of certain mRNAs and promote their turnover. The ideal binding site appears to be UUAU UUAUU, although variations of this sequence can be tolerated with relatively minor changes in affinity (1-5). TTP and its other family members can bind with high affinity to these AREs and then promote the removal of the poly(A) tail and the ultimate destruction of the transcript (6).The protein members of the TTP family in mice are as follows: TTP itself, encoded by Zfp36; ZFP36L1, also known as BRF1, ERF1, and CMG1, encoded by Zfp36l1; ZFP36L2, also known as BRF2 and ERF2, encoded by Zfp36l2; and ZFP36L3, encoded by Zfp36l3. The identification of TTP, the best-studied member of this family, as an mRNA-destabilizing protein was first recognized by analyzing the phenotype of TTP knockout (KO) mice, which exhibited a severe systemic inflammatory phenotype with polyarticular erosive arthritis, weight loss, dermatitis, autoimmunity, and myeloid hyperplasia (7). The nature of this syndrome suggested excess tumor necrosis factor alpha (TNF) as a causative agent. This was confirmed by the observations that treatment with anti-TNF antibodies or interbreeding the TTP KO mice with mice lacking both TNF receptors prevented the development of the inflammatory phenotype (7,8). Subsequent studies on bone marrow-derived macrophages from these animals demonstrated that the TNF mRNA is a direct target of TTP and that the binding of TTP to binding sites in the 3=UTR of TNF mRNA could promote its decay (9, 10).Since the early demonstration...